Curated News
By: NewsRamp Editorial Staff
June 05, 2025
Scinai Immunotherapeutics Cleared to Acquire Pincell, Expanding I&I Pipeline
TLDR
- Scinai Immunotherapeutics gains a strategic edge by acquiring Pincell S.r.l., enhancing its inflammation and immunology pipeline with PC111, a promising monoclonal antibody.
- Scinai Immunotherapeutics secures Italy’s Golden Power clearance to acquire Pincell S.r.l., pending a €12 million grant, expanding its I&I pipeline with PC111.
- Scinai’s acquisition of Pincell S.r.l. advances treatment for severe skin disorders, leveraging PC111’s Orphan Drug Designation to improve patient outcomes globally.
- Scinai Immunotherapeutics steps closer to acquiring Pincell S.r.l., bringing PC111 into its portfolio, a novel treatment for Pemphigus and severe skin conditions.
Impact - Why it Matters
This acquisition represents a pivotal step in advancing treatments for severe skin disorders and other inflammation and immunology-related conditions. By integrating Pincell's innovative monoclonal antibody, PC111, into its pipeline, Scinai is poised to address significant unmet medical needs, offering hope to patients worldwide. The strategic expansion underscores the importance of international collaboration in biotech innovation and the potential for groundbreaking therapies to emerge from such partnerships.
Summary
Scinai Immunotherapeutics (NASDAQ: SCNI) has achieved a significant milestone by receiving regulatory clearance under Italy's Golden Power regulation to proceed with its option to acquire 100% of Pincell S.r.l., an Italian biotech company. This approval, granted by Italy's Coordination Group and Ministry of Health, marks a strategic expansion for Scinai into the inflammation and immunology sector. Pincell's lead asset, PC111, a monoclonal antibody targeting the Fas/FasL pathway, has been granted Orphan Drug Designation for Pemphigus and is under development for severe skin disorders. The acquisition is pending final conditions, including a €12 million grant decision anticipated later this summer. For more details, visit the full press release.
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company with a dual focus: developing innovative biological therapeutic products for inflammation and immunology, and offering comprehensive CDMO services to early-stage biotech companies. Their pioneering work in NanoAbs targets diseases with significant unmet medical needs. Discover more about their groundbreaking work at www.Scinai.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Immunotherapeutics Cleared to Acquire Pincell, Expanding I&I Pipeline
